


## Amaxa<sup>®</sup> Human Macrophage Nucleofector<sup>®</sup> Kit


### For Human Macrophages

Suitable for Macrophages differentiated from human peripheral blood mononuclear cells (PBMC). PBMC should be purified from fresh human blood samples treated with an anticoagulant or from leukocyte-enriched buffy coat. Macrophages are large granular cells which adhere to plastic surfaces.


### Example for Nucleofection<sup>®</sup> of Human Macrophages



**Example for the transfection of human macrophages with pmaxGFP<sup>®</sup> Vector.** Primary human macrophages were transfected by Nucleofection<sup>®</sup> using the Human Macrophage Nucleofector<sup>®</sup> Kit with pmaxGFP<sup>®</sup> Vector. 24 hours post Nucleofection<sup>®</sup> cells were analyzed by light (A) and fluorescence microscopy (B) at 40x magnification. Transfected macrophages reveal cytoplasmic extrusions important for phagocytic function of macrophages.



**Transfection efficiency of human macrophages 24 hours post Nucleofection<sup>®</sup>.** Cells were transfected by Nucleofection<sup>®</sup> with program Y-010 and 2 µg of pmaxGFP<sup>®</sup> Vector. Cell viability (%7-AAD negative) is 88%.



**Human Macrophages can be stimulated after Nucleofection<sup>®</sup>.** Primary human macrophages were transfected with 2 µg pmaxGFP<sup>®</sup> Vector. 24 hours post Nucleofection<sup>®</sup> the culture medium was changed and cells were stimulated with LPS. 48 hours post Nucleofection<sup>®</sup> TNF α secretion was determined by ELISA. In all three samples stimulated with LPS a comparable TNF α production could be detected. In non-stimulated samples no TNF α was detected.

### Product Description

Cat. No.	VPA-1008
Size (Reactions)	25
Human Macrophage Nucleofector <sup>®</sup> Solution	2.25 ml (2.05 ml + 10% overfill)
Supplement	0.5 ml (0.45 ml + 10% overfill)
pmaxGFP <sup>®</sup> Vector (0.5 µg/µl in 10 mM Tris pH 8.0)	30 µg
Certified Cuvettes	25
Plastic Pipettes	25
Storage and stability	Store Nucleofector <sup>®</sup> Solution, Supplement and pmaxGFP <sup>®</sup> Vector at 4°C. For long-term storage, pmaxGFP <sup>®</sup> Vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector <sup>®</sup> Supplement is added to the Nucleofector <sup>®</sup> Solution it is stable for three months at 4°C.

## Required Material

**Note** Please make sure that the entire supplement is added to the Nucleofector® Solution. The ratio of Nucleofector® Solution to supplement is 4.5:1. For a single reaction use 82 µl of Nucleofector® Solution plus 18 µl of supplement to make 100 µl of total reaction volume.

- Nucleofector® Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP® Vector
- Substrate of interest, highly purified, preferably by using endotoxin free Kits; A260 : A280 ratio should be at least 1.8
- 12-well culture dish or culture dish of your choice
- Culture dish for differentiation: Poly-D-Lysine coated flasks [Becton Dickinson; Cat.No. 354537]
- **For detaching cells:** 0.5 mg/ml trypsin, 0.2 mg/ml EDTA in PBS for 25 minutes
- **Differentiation medium:** RPMI 1640 [Lonza; Cat.No. 12-167F] supplemented with 10% fetal calf serum (FCS), 100µg/ml streptomycin, 100 U/ml penicillin, and 2 mM glutamine, 1% Na-pyruvate, 1% NEAA [Non-Essential Amino Acids] and 50 ng/ml rHu M-CSF
- **Culture medium:** Macrophage-SFM [Invitrogen; Cat.No. 12065-074] supplemented with 10% FCS and 2 mM glutamine
- **For isolation:** PBS with 0.5% BSA (PBS/BSA); Ficoll-Paque™ Plus [GE Healthcare; Cat.No. 17-1440-03]
- Prewarm appropriate volume of culture media to 37°C (2 ml per sample)
- Appropriate number of cells (5 – 7 x 10<sup>5</sup> cells per sample; lower or higher cell numbers may influence transfection results)

## 1. Pre Nucleofection®

### Blood samples

- 1.1 Fresh human blood treated with an anticoagulant (e.g. heparin, citrate, ACD-A) or alternatively, leukocyte-enriched buffy coat not older than 8 hours. The samples should be diluted with 2 – 4 volumes of PBS/BSA

### Preparation of PBMC

- 1.2 Pipet 15 ml Ficoll-Paque™ Plus in a 50 ml conical tube
- 1.3 Overlay Ficoll- Paque™ Plus with 35 ml blood sample and centrifuge at 750xg for 20 minutes at 20°C in a swinging-bucket rotor without brake
- 1.4 Remove the upper layer leaving the mononuclear cell layer undisturbed at the interphase. Carefully transfer the interphase cells (lymphocytes and monocytes) to a new 50 ml conical tube
- 1.5 Add PBS/BSA to 50 ml mark, mix and centrifuge at 350xg for 10 minutes at 4°C. Remove the supernatant carefully
- 1.6 Resuspend the cell pellet in 25 ml of PBS/BSA and centrifuge at 160xg for 15 minutes at 4°C. Remove the supernatant carefully
- 1.7 Resuspend the cell pellet in 25 ml PBS/BSA and centrifuge at 300xg for 10 minutes at 4°C. Remove the supernatant carefully

- 1.8 Resuspend cell pellet in 5 ml PBS/BSA and count the cells

### Differentiation of macrophages

---

- 1.9 Plate  $5 \times 10^7$  PBMC per  $75 \text{ cm}^2$  Poly-D-Lysine coated flask
- 1.10 Enrich monocyte population by plastic adherence for 1 – 2 hours in an incubator at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  atmosphere
- 1.11 Discard supernatant with non-adherent cells and wash adherent monocytes 1x with 15 ml prewarmed PBS per flask. Aspirate washing solution.
- 1.12 Add 10 ml differentiation media to each flask and differentiate monocytes for 7 days into macrophages
- 1.13 Replace media 2 – 3x during the differentiation period

### Trypsinization

---

- 1.14 Wash adherent macrophages once with PBS
- 1.15 Add Trypsin/EDTA solution (0.5 mg/ml trypsin and 0.2 mg/ml EDTA in PBS) to cover the cell monolayer (~3 ml per  $75 \text{ cm}^2$  flask), and gently swirl the dish/flask to ensure an even distribution of the solution. Incubate the flask for 25 – 30 minutes at RT
- 1.16 Stop trypsinization by addition of supplemented RPMI without rHu M-CSF

## 2. Nucleofection®

### One Nucleofection® Sample contains

---

5 – 7  $\times 10^5$  cells

2 – 5  $\mu\text{g}$  plasmid DNA (in 1 – 5  $\mu\text{l}$   $\text{H}_2\text{O}$  or TE) or 2  $\mu\text{g}$  pmaxGFP® Vector or 30 – 300 nM siRNA (3 – 30 pmol/sample)

100  $\mu\text{l}$  Human Macrophage Nucleofector® Solution

---

- 2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution
- 2.2 Prepare 12-well plates by filling appropriate number of wells with 1.5 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified  $37^\circ\text{C}/5\% \text{CO}_2$  incubator
- 2.3 Count the cells and determine cell density
- 2.4 Centrifuge the required numbers of cells (5 – 7  $\times 10^5$  cells per sample) at 200xg for 10 minutes at room temperature. Discard supernatant completely so that no residual media covers the cell pellet
- 2.5 Resuspend the cell pellet carefully in 100  $\mu\text{l}$  room temperature Nucleofector® Solution per sample. Avoid storing the cell suspension longer than 20 minutes in Human Macrophage Nucleofector® Solution, as this reduces cell viability and gene transfer efficiency
- 2.6 Combine 100  $\mu\text{l}$  of cell suspension with 1 – 5  $\mu\text{g}$  DNA, 2  $\mu\text{g}$  pmaxGFP® Vector or 30 – 300 nM siRNA (3 – 30 pmol sample) or other substrates
- 2.7 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap
- 2.8 Select the appropriate Nucleofector® Program Y-010 (Y-10 for Nucleofector® I Device)
- 2.9 Insert the cuvette with cell/DNA suspension into the Nucleofector® Cuvette Holder and apply the selected program
- 2.10 Take the cuvette out of the holder once the program is finished

- 2.1.1 Add ~500  $\mu$ l of the pre-equilibrated supplemented culture medium to the cuvette and gently transfer the sample into the 12-well plate (final volume of 2 ml media per well). Use the supplied pipettes and avoid repeated aspiration of the sample

---

### 3. Post Nucleofection®

- 3.1 Gene expression should be analyzed at different time points

**Note** For flow cytometry analysis we recommend harvesting cells by trypsin treatment. Do not use cell scraper.

- 3.2 For activation experiments replace medium 24 hours post Nucleofection® and add 1  $\mu$ g/ml LPS to the fresh culture medium

- 3.3 Activation markers (e.g. TNF  $\alpha$ ) can be analyzed 24 hours after activation

**Note** It is known that macrophages respond to intracellular foreign DNA by activation (see additional information). Nucleofection® of plasmid DNA causes transient activation of macrophages which is indicated by transient TNF  $\alpha$  secretion for up to 24 hours after Nucleofection®. It is possible to reactivate macrophages after medium change 24 hours post Nucleofection®.

## Additional Information

For an up-to-date list of all Nucleofector® References, please refer to:  
[www.lonza.com/nucleofection-citations](http://www.lonza.com/nucleofection-citations)

**For more technical assistance, contact our Scientific Support Team:**

USA/Canada  
Phone: 800 521 0390 (toll-free)  
Fax: 301 845 8338  
E-mail: [scientific.support@lonza.com](mailto:scientific.support@lonza.com)

Europe and Rest of World  
Phone: +49 221 99199 400  
Fax: +49 221 99199 499  
E-mail: [scientific.support.eu@lonza.com](mailto:scientific.support.eu@lonza.com)

## References:

1. Hacker G. et al. (2002). Immunology 105(3):245-251

**Lonza Cologne AG**  
50829 Cologne, Germany

Please note that the Amaxa® Nucleofector® Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.

Amaxa, Nucleofector, Nucleofection and maxGFP are registered trademarks of the Lonza Cologne AG in Germany and/or U.S. and/or other countries.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at [license@evrogen.com](mailto:license@evrogen.com).

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtaining of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2009, Lonza Cologne AG. All rights reserved DPA-1009 08/09